Neural Control Market Report 2026

The neural control market size has grown rapidly in recent years. It will grow from $2.48 billion in 2025 to $2.81 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to growth of neuroprosthetics research, expansion of rehabilitation robotics, rising paralysis treatment demand, advances in neural electrodes, increase in neurostimulation therapies.

The neural control market size is expected to see rapid growth in the next few years. It will grow to $4.72 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to rising demand for bci solutions, expansion of assistive exoskeletons, growth of neural rehabilitation tech, increase in neurotech funding, broader clinical neural interface adoption. Major trends in the forecast period include brain computer interface integration, implantable neural interface devices, wearable neuro signal sensors, closed loop neurostimulation systems, neuro controlled assistive robotics.

The growing prevalence of neurological disorders is anticipated to drive the expansion of the neural control market in the future. Neurological disorders are medical conditions that affect the brain, spinal cord, or nerves, leading to impairments in movement, sensation, cognition, or other bodily functions. This increasing prevalence is driven by aging populations, which heighten the risk of conditions such as Alzheimer’s and Parkinson’s, contributing to a growing global healthcare burden. Neural control helps address the increasing prevalence of neurological disorders by enabling precise monitoring, modulation, and rehabilitation of neural activity, improving patient outcomes and symptom management. For example, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, 6.7 million Americans aged 65 and older have Alzheimer’s, projected to rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the neural control treatment market.

Leading companies operating in the neural control market are focusing on advancements in neural interface technologies, such as BCI-enabled consumer-grade devices, to enhance human-machine interaction, improve cognitive performance, and provide seamless control over digital and physical environments. A BCI-enabled consumer-grade device is an electronic device designed for everyday use by non-experts that incorporates brain-computer interface (BCI) technology to detect, interpret, and respond to neural signals from the user’s brain. For example, in September 2024, Neurable Inc., a US-based neurotechnology company, launched the MW75 Neuro, smart headphones integrated with its AI-powered BCI technology, in partnership with premium audio brand Master & Dynamic. The MW75 Neuro incorporates EEG sensors within the ear pads to capture brainwave data, offering focus tracking, burnout management, and personalized productivity tips via the Neurable mobile app. Its transformative AI platform provides lab-level accuracy in interpreting brain signals, while the headphones also deliver premium audio quality, adaptive noise cancellation, and ergonomic comfort. This product represents a major step in making noninvasive BCI technology accessible in everyday consumer devices.

In November 2024, Boston Scientific Corporation, a US-based provider of advanced medical technologies and high-performance solutions, acquired Axonics Inc. for approximately $3.7 billion. Through this acquisition, Boston Scientific intends to expand its urology portfolio and enter the high-growth sacral neuromodulation market by incorporating Axonics’s specialized devices for urinary and bowel dysfunction into its product lineup, enhancing both its technological capabilities and global patient reach. Axonics Inc. is a US-based company that designs implantable sacral neuromodulation systems to treat urinary and bowel disorders.

Major companies operating in the neural control market are Boston Scientific Corporation, Synchron Inc., Neuralink Corp., NeuroSky Inc., Emotiv Inc., BrainCo Inc., Brain Products GmbH, Paradromics Inc., Neuroelectrics S.L.U., g.tec medical engineering GmbH, Neurable Inc., Advanced Brain Monitoring Inc., Bitbrain Technologies S.L., Cortec GmbH, BrainGate Inc., OpenBCI LLC, Cognixion Inc., Alea Neurotherapeutics SA, Nexstem Technologies Pvt. Ltd., AAVAA Inc.

Tariffs on electronic components, biosensors, and precision implants are influencing the neural control market by raising device manufacturing costs. Hardware intensive segments such as implantable electrodes, neurostimulators, and brain computer interface devices are most affected. Import dependent medical device markets in north america and europe face higher procurement prices. These added costs can slow adoption in smaller clinical centers and research labs. However, tariffs are also encouraging localized neuro device manufacturing and regional supplier ecosystems.

The neural control market research report is one of a series of new reports that provides neural control market statistics, including neural control industry global market size, regional shares, competitors with a neural control market share, detailed neural control market segments, market trends and opportunities, and any further data you may need to thrive in the neural control industry. This neural control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neural control is the process by which the nervous system governs and coordinates the actions of muscles, organs, and physiological functions through electrical and chemical signals, enabling movement, sensation, reflexes, and internal regulation. It involves integrating sensory inputs, central processing in the brain and spinal cord, and motor outputs to maintain balance, adaptability, and purposeful behavior in living organisms.

The core components of neural control systems consist of hardware, software, and services. Hardware refers to physical devices and equipment used to monitor, interface with, and control neural signals for a variety of applications. These solutions operate through different modes, including invasive and non-invasive, and leverage technologies such as brain-computer interfaces, neurostimulation, and neuroprosthetics. They are applied across healthcare, robotics, automotive, consumer electronics, and other fields, and cater to end users including medical institutions, research organizations, industrial users, and other stakeholders.

The neural control market consists of sales of brain-computer interface devices, neuroprosthetic limbs, neural stimulation devices, wearable neural sensors, implantable neural electrodes, robotic exoskeletons, electroencephalography headsets, and transcranial stimulation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.